Cabergoline Versus GnRH Antagonist Rescue and Cabergoline in the Prevention of Ovarian Hyperstimulation Syndrome
Launched by ALJAZEERA HOSPITAL · Jun 2, 2015
Trial Information
Current as of June 25, 2025
Unknown status
Keywords
ClinConnect Summary
Ovarian hyperstimulation syndrome (OHSS) is the most serious complication of assisted reproduction. Complications of OHSS include vascular thrombosis, pulmonary embolism, renal failure, electrolyte disturbances, ascites, hydrothorax ,torsion of the ovary, abortion or rarely death.
Previous studies revealed that converting a long GnRH agonist cycle to an GnRH antagonist cycle (GnRH antagonist rescue) reduced the risk of OHSS. Other studies revealed that cabergoline (potent dopamine receptor agonist on D2 receptors)was effective in preventing OHSS.
The aim of study is to compare the efficac...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Patients undergoing ovarian stimulation for IVF-ET with long GnRH agonist protocol and at high risk of developing OHSS \[ have more than 20 follicles ( 90% of them less than 14 mm in mean diameter) and serum estradiol ≥ 3000 pg/ml\]
- Exclusion Criteria:
- • Fibrosis of lung,
- • swelling or inflammation around the heart or lung,
- • hypertension,
- • liver disease,
- • heart valve disease and
- • allergy to cabergoline or ergot derivatives.
About Aljazeera Hospital
Aljazeera Hospital is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. Committed to the highest standards of ethical practices and patient safety, Aljazeera Hospital collaborates with renowned researchers and healthcare professionals to explore new treatments and therapies. With a state-of-the-art facility and a multidisciplinary team, the hospital aims to contribute to the global medical community by facilitating cutting-edge studies that address pressing health challenges. Through its rigorous clinical trial programs, Aljazeera Hospital seeks to enhance the quality of care and foster breakthroughs that benefit patients both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Giza, , Egypt
Patients applied
Trial Officials
Usama M Fouda, M.D,PhD
Study Chair
Aljazeera (Al Gazeera) hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials